Nature Communications

Novel cell therapy treatments offer promise to immune-compromised children

Retrieved on: 
Donnerstag, April 18, 2024

Without this therapy, estimates suggest that less than 30% of patients would recover, using standard protocols.

Key Points: 
  • Without this therapy, estimates suggest that less than 30% of patients would recover, using standard protocols.
  • , the paper’s first author and the Translational Research Laboratory director at the Children’s National Cell Enhancement and Technologies for Immunotherapy (CETI) program.
  • They combined the expertise at Children’s National in producing and banking cell therapy products with the community built around the PTCTC.
  • In the decade ahead, Dr. Bollard sees promise in cell therapies for patients with cancer, immune deficiencies after transplant and dozens of other disorders, including genetic and autoimmune diseases.

Seed Health Launches Computational Biology Platform, Powered by Most Comprehensive Host-Microbiome Data Set, to Expand Pipeline Beyond the Gut

Retrieved on: 
Donnerstag, April 11, 2024

BOSTON, April 11, 2024 /PRNewswire/ -- Seed Health today launched CODA, a computational biology platform for the discovery and development of next-generation precision probiotics and microbiome-directed interventions. The platform is powered by the Human Phenotype Project—the world's most comprehensive multi-omics data set, emerging from the lab of computational biologist Professor Eran Segal, Ph.D., at the Weizmann Institute of Science. CODA elucidates previously unknown connections between the microbiome and health to develop targeted, outcome-specific interventions. First programs include cardiometabolic health, brain health, menopause, and longevity.

Key Points: 
  • "Our CODA platform is tracking the health data of tens of thousands of individuals over decades, offering a comprehensive, multi-omics perspective," explained Raja Dhir, Co-Founder of Seed Health.
  • Such insights reveal a clear distinction between biological and chronological age, offering a more comprehensive understanding of health and disease patterns.
  • This comprehensive approach allows us to unravel the complex interactions between diet, supplementation, the microbiome, and multi-system human health more effectively than before."
  • "CODA significantly expands our platform's capacity to realize the full promise of the microbiome," said Ara Katz, Co-CEO and Co-Founder of Seed Health.

Climate change is depleting deep sea oxygen, but tides are helping to keep the ocean healthy

Retrieved on: 
Dienstag, April 23, 2024

That’s one reason an oxygen deficit deep in the oceans is a problem – and climate change is making it worse.

Key Points: 
  • That’s one reason an oxygen deficit deep in the oceans is a problem – and climate change is making it worse.
  • This is important because creatures in the ocean are reliant on oxygen to survive in the same way as animals on land are.
  • The tides act to stir up deep water nutrients, which promote the growth of microscopic plants known as phytoplankton.
  • Every Wednesday, The Conversation’s environment editor writes Imagine, a short email that goes a little deeper into just one climate issue.

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Retrieved on: 
Donnerstag, April 4, 2024

The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.

Key Points: 
  • The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.
  • The paper describes Sensei Biotherapeutics’ approach to the discovery and development of SNS-101, which was designed to potently and selectively target the active protonated form of VISTA, a protein that plays a significant role in suppressing T-cell activation.
  • SNS-101 is designed to block VISTA by inhibiting its interaction with PSGL-1 on T-cells resulting in T-cell activation.
  • The manuscript published in Nature Communications is entitled “VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response,” and can be found here: https://rdcu.be/dDF8x

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Retrieved on: 
Donnerstag, März 28, 2024

“In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.

Key Points: 
  • “In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.
  • We believe that we are well-positioned, both financially and scientifically, to execute our strategic plan with enhanced capabilities and resources.
  • For the year ended December 31, 2023, the Company received a total of approximately $1.3 million in connection with the sale of Alphazyme LLC.
  • Other Income: For the year ended December 31, 2023, the Company had a gain of approximately $1,018,000 from the sale of the Company’s equity interest in Alphazyme, LLC.

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

Retrieved on: 
Dienstag, März 26, 2024

The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO.

Key Points: 
  • The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO.
  • "The study characterized the in vitro activity of a monoclonal antibody (mAb) produced by C1 cells (designated "HuMab 87G7") and demonstrated its protective efficacy for both prophylactic and therapeutic applications in hamsters and non-human primates without causing antibody-mediated enhanced virus replication.
  • A mounting body of evidence, from both ourselves and an expanding community of scientists worldwide, supporting the use of Dyadic's C1 expression system as a versatile production platform.
  • To view the online publication of “Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models”, please visit nature communications or follow the link below:

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
Dienstag, April 9, 2024

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

rHEALTH's Publication in Nature Communications Highlights Its Powerful Lab Diagnostics for Astronauts

Retrieved on: 
Freitag, April 5, 2024

BEDFORD, Mass., April 5, 2024 /PRNewswire-PRWeb/ -- rHEALTH today announced that, in partnership with NASA, that its study of the rHEALTH ONE universal biomedical analyzer on the International Space Station (ISS), was published in Nature Communications. The article, titled, "Single Drop Cytometry Onboard the International Space Station" performs detailed analysis of the data collected by the rHEALTH ONE device.

Key Points: 
  • The publication shows sophisticated laboratory diagnostics can be implemented successfully in environments previously thought to be too unforgiving and challenging.
  • Astronauts traveling to the Moon and Mars require immediate health information, just like all of us on Earth.
  • The study supports the ability to perform real-time lab analysis for astronauts in a microgravity environment, paving the way for human missions to the Moon and Mars.
  • This study further supports our mission to bring more powerful diagnostics outside conventional hospital settings," said Eugene Chan MD, Founder and CEO of rHEALTH.

MiNK Reports Fourth Quarter and Year-End 2023 Results

Retrieved on: 
Donnerstag, März 21, 2024

MiNK executives will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • MiNK executives will host a conference call and webcast at 8:30 a.m.
  • “In 2023, MiNK made significant strides in advancing our allogeneic iNKT cell programs, contributing to a growing body of clinical data that underscores the unique advantages of iNKTs and their pivotal role in immunity,” said Dr. Jennifer Buell, Chief Executive Officer and President at MiNK.
  • The study reports survival rates exceeding 70% among patients on mechanical ventilation and surpassing 80% among those receiving VV ECMO support.
  • These results stand in stark contrast to the 10% survival rate observed in the in-hospital control during the same period.

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Donnerstag, März 14, 2024

“For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.

Key Points: 
  • “For now, we remain fully focused on preparing for a potential obe-cel launch and successfully transitioning Autolus to a commercial stage company.
  • In February 2024, Autolus promoted Dr. Chris Williams to Chief Business Officer and Alex Driggs to Senior Vice President, Legal Affairs and General Counsel.
  • Dr. Leiderman brings extensive transactional and financial expertise, and Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to Autolus’ Board.
  • Financial Results for the Year Ended December 31, 2023